Volume 12 Issue 1, March 2018

ImmuneOncia Therapeutics is developing antibodies that target novel immune checkpoints, which could enhance drug efficacy when used in combination with agents that block PD-1 or PD-L1.

Carrick Therapeutics is collaborating with a network of researchers and partners to build an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.

Halozyme is pioneering therapies that remodel the tumor microenvironment to increase accessibility for chemotherapies, immuno-oncology agents, and innate immune cells. Halozyme is developing pegvorhyaluronidase alfa (PEGPH20) to treat pancreatic and other solid tumors.

A lean, entrepreneurial approach is enabling specialty pharma company EUSA Pharma to outcompete larger rivals.

BioMarker Strategies has developed an innovative approach to enable more accurate prediction of patient response to targeted treatments for solid tumors.

Mitra Biotech is advancing CANscript, a fully human, clinically validated, ex vivo platform for oncology drug programs. Mitra is looking to expand its broad network of pharma and biotech collaborators to further advance promising oncology candidates to and through the clinic.

Arquer Diagnostics is developing a series of innovative, non-invasive tests for cancer and recently launched ADXBLADDER, a reliable urine test for bladder cancer.

In just four years, Cinfa Biotech’s pegfilgrastim biosimilar has been developed, been tested, and received acceptance from the European Medicines Agency for review of a marketing authorization application to treat neutropenia.